Welcome to our dedicated page for Endra Life Sciences SEC filings (Ticker: NDRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to gauge how soon ENDRA Life Sciences will turn its TAEUS ultrasound into revenue or how much cash remains for pivotal trials? Those answers hide inside ENDRA Life Sciences SEC filings, from 8-K updates on FDA feedback to 10-K footnotes on R&D burn. This page gathers every document and quietly addresses questions investors actually search, such as “ENDRA Life Sciences SEC filings explained simply.”
Stock Titan’s AI reads each new submission the moment it reaches EDGAR and produces clear highlights—no legalese. View an “ENDRA Life Sciences quarterly earnings report 10-Q filing,” launch an “ENDRA Life Sciences earnings report filing analysis,” or scan “ENDRA Life Sciences insider trading Form 4 transactions” in minutes. Real-time alerts surface Form 4 insider buys, shelf registrations, or partnership announcements so you catch material events before the market does.
Need deeper context? Our tools connect filings to what drives ENDRA’s valuation:
- “ENDRA Life Sciences annual report 10-K simplified” pinpoints TAEUS commercialization timelines, patent counts, and cash runway.
- “ENDRA Life Sciences proxy statement executive compensation” clarifies milestones that trigger bonuses for clinical progress.
- “ENDRA Life Sciences 8-K material events explained” summarizes FDA correspondence and strategic alliances within minutes.
- “ENDRA Life Sciences Form 4 insider transactions real-time” maps each executive trade against trial readouts.
With AI-powered summaries, expert commentary, and comprehensive coverage of all forms, you can start “understanding ENDRA Life Sciences SEC documents with AI” and turn dense reports into clear insight.
On June 11, 2025, ENDRA Life Sciences Inc. (NDRA) filed a Form 4 showing that director Lou Basenese was granted 5,384 restricted stock units (RSUs), convertible to common stock on a one-for-one basis. The award, recorded at a transaction price of $0, reflects routine equity compensation rather than an open-market purchase. All RSUs vest in full on June 11, 2026. After the grant, Basenese beneficially owns 5,385 NDRA common shares, held directly. No derivative securities, sales, or dispositions were reported. Given the modest share count relative to ENDRA’s total float, the filing is viewed as neutral in financial materiality, but it marginally improves insider-shareholder alignment.
On June 11, 2025, ENDRA Life Sciences (NDRA) director Michael Harsh received 5,384 restricted stock units (RSUs), as disclosed in a Form 4 filed on July 1, 2025. The RSUs carry an exercise price of $0 and convert to common stock on a one-for-one basis.
Vesting schedule: the entire award vests on June 11, 2026. After the grant, Harsh beneficially owns 5,386 NDRA common shares, held directly. No derivative instruments or share disposals were reported, and no cash changed hands.
This appears to be a routine equity-compensation grant designed to encourage long-term alignment between the director and shareholders. The transaction is too small to impact NDRA’s share count, earnings or liquidity, but it does marginally increase insider ownership.
ENDRA Life Sciences Inc. (NDRA) filed a Form 4 on 1 July 2025 for director Anthony DiGiandomenico. On 11 June 2025 the director was granted 5,384 restricted stock units (RSUs) that convert to common shares on a 1-for-1 basis and vest in full on 11 June 2026. No cash was exchanged (reported price = $0), indicating a routine equity-compensation award rather than an open-market purchase. After the grant, DiGiandomenico’s direct beneficial ownership increased to 5,443 common shares, implying a prior holding of about 59 shares. No derivative transactions or dispositions were disclosed. The filing modestly tightens insider-shareholder alignment but, given the small number of shares relative to ENDRA’s total float, the market impact is expected to be limited.
FAQ
What is the current stock price of Endra Life Sciences (NDRA)?
What is the market cap of Endra Life Sciences (NDRA)?
What is the primary focus of ENDRA Life Sciences Inc?
How does the Nexus 128 system differ from conventional imaging systems?
What is TAEUS and how is it utilized?
Who are the typical users of ENDRA Life Sciences' imaging systems?
Which conditions does TAEUS aim to diagnose?
How does ENDRA Life Sciences maintain its competitive position?
